# Taiga Nishihori

List of Publications by Year
in descending order



| 144 | 3,787 | 147726 | 168321 |
|---|---|---|---|
| papers | citations | 31 h-index | 53 g-index |

| 152 | 152 | 152 | 4902 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. Blood, 2014, 124, 2596-2606. | 0.6 | 228 |
| 2 | Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. Journal of Clinical Oncology, 2015, 33, 3741-3749. | 0.8 | 163 |
| 3 | Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood, 2021, 137, 2621-2633. | 0.6 | 137 |
| 4 | High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Advances, 2020, 4, 3268-3276. | 2.5 | 134 |
| 5 | Trends in Utilization and Outcomes of Autologous Transplantation as Early Therapy for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2013, 19, 1615-1624. | 2.0 | 99 |
| 6 | Salvage Second Hematopoietic Cell Transplantation inÂMyeloma. Biology of Blood and Marrow Transplantation, 2013, 19, 760-766. | 2.0 | 98 |
| 7 | Hematopoietic Cell Transplant Comorbidity Index Is Predictive of Survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2014, 20, 402-408.e1. | 2.0 | 98 |
| 8 | Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse. JAMA Oncology, 2018, 4, 1245. | 3.4 | 97 |
| 9 | Extracorporeal Photopheresis in Steroid-Refractory Acute or Chronic Graft-versus-Host Disease: Results of a Systematic Review of Prospective Studies. Biology of Blood and Marrow Transplantation, 2014, 20, 1677-1686. | 2.0 | 95 |
| 10 | Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Advances, 2019, 3, 1826-1836. | 2.5 | 89 |
| 11 | Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood, 2021, 137, 3291-3305. | 0.6 | 85 |
| 12 | A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica, 2012, 97, 1882-1889. | 1.7 | 82 |
| 13 | Diagnostic and Therapeutic Advances in Blastic Plasmacytoid Dendritic Cell Neoplasm: A Focus onÂHematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1006-1012. | 2.0 | 75 |
| 14 | Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. Bone Marrow Transplantation, 2018, 53, 535-555. | 1.3 | 75 |
| 15 | Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 726-733. | 2.0 | 71 |
| 16 | The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. Blood Advances, 2019, 3, 670-680. | 2.5 | 71 |
| 17 | Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report. Cancer, 2017, 123, 3141-3149. | 2.0 | 65 |
| 18 | Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. Transplantation and Cellular Therapy, 2021, 27, 642-649. | 0.6 | 65 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Survival following allogeneic transplant in patients with myelofibrosis. Blood Advances, 2020, 4, 1965-1973. | 2.5 | 63 |
| 20 | Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. Journal of Clinical Oncology, 2016, 34, 1864-1871. | 0.8 | 61 |
| 21 | Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. Leukemia, 2018, 32, 986-995. | 3.3 | 60 |
| 22 | Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. British Journal of Haematology, 2017, 179, 781-789. | 1.2 | 56 |
| 23 | HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide. Blood, 2022, 139, 1452-1468. | 0.6 | 52 |
| 24 | Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. Journal of Hematology and Oncology, 2010, 3, 36. | 6.9 | 47 |
| 25 | Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2019, 54, 1254-1265. | 1.3 | 47 |
| 26 | Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel. Clinical Cancer Research, 2020, 26, 4823-4831. | 3.2 | 47 |
| 27 | Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia, 2021, 35, 2672-2683. | 3.3 | 45 |
| 28 | Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Journal of Hematology and Oncology, 2013, 6, 2. | 6.9 | 42 |
| 29 | Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injuryâ€“Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant. JAMA Network Open, 2020, 3, e1918668. | 2.8 | 40 |
| 30 | Clinical Outcomes of Patients With Plasma Cell Leukemia in the Era of Novel Therapies and Hematopoietic Stem Cell Transplantation Strategies: A Single-Institution Experience. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 507-511. | 0.2 | 37 |
| 31 | Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphomas as Front-Line Consolidation or in the Relapsed/Refractory Setting: A Systematic Review/Meta-Analysis. Biology of Blood and Marrow Transplantation, 2016, 22, 802-814. | 2.0 | 37 |
| 32 | ATG Prevents Severe Acute Graft-versus-Host Disease in Mismatched Unrelated Donor Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 1237-1244. | 2.0 | 35 |
| 33 | Comparative Analysis of Calcineurin Inhibitorâ€“Based Methotrexate and Mycophenolate Mofetilâ€“Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 73-85. | 2.0 | 35 |
| 34 | Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Advances, 2022, 6, 339-357. | 2.5 | 35 |
| 35 | Post-Transplant Outcomes in High-Risk Compared with Nonâ€“High-Risk Multiple Myeloma: A CIBMTR Analysis. Biology of Blood and Marrow Transplantation, 2016, 22, 1893-1899. | 2.0 | 34 |
| 36 | Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. Biology of Blood and Marrow Transplantation, 2016, 22, 248-257. | 2.0 | 33 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation. Haematologica, 2017, 102, 948-957. | 1.7 | 33 |
| 38 | Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival. Biology of Blood and Marrow Transplantation, 2018, 24, 478-485. | 2.0 | 31 |
| 39 | Dysglycemia Following Glucocorticoid Therapy for Acute Graft-versus-Host Disease Adversely Affects Transplantation Outcomes. Biology of Blood and Marrow Transplantation, 2011, 17, 239-248. | 2.0 | 28 |
| 40 | Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations. Immunotherapy, 2016, 8, 435-447. | 1.0 | 28 |
| 41 | Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Blood Advances, 2021, 5, 1648-1659. | 2.5 | 28 |
| 42 | Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia, 2020, 34, 3338-3347. | 3.3 | 27 |
| 43 | Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors. Blood Advances, 2021, 5, 975-983. | 2.5 | 27 |
| 44 | Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease. Annals of Transplantation, 2010, 15, 21-9. | 0.5 | 27 |
| 45 | A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation. Blood Advances, 2021, 5, 1154-1163. | 2.5 | 26 |
| 46 | In vivo IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation. Haematologica, 2018, 103, 531-539. | 1.7 | 25 |
| 47 | Carpal Tunnel Syndrome Associated with the Use of Aromatase Inhibitors in Breast Cancer. Clinical Breast Cancer, 2008, 8, 362-365. | 1.1 | 24 |
| 48 | Incidence and Management of Colorectal Cancer in Liver Transplant Recipients. Clinical Colorectal Cancer, 2008, 7, 260-266. | 1.0 | 23 |
| 49 | Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome. Bone Marrow Transplantation, 2015, 50, 1057-1062. | 1.3 | 23 |
| 50 | Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma. Blood Advances, 2020, 4, 4086-4090. | 2.5 | 22 |
| 51 | Bortezomib salvage followed by a <scp>P</scp>hase <scp>I</scp>/<scp>II</scp> study of bortezomib plus highâ€dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. British Journal of Haematology, 2012, 157, 553-563. | 1.2 | 21 |
| 52 | Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine. Blood Advances, 2018, 2, 1198-1206. | 2.5 | 21 |
| 53 | Increased Infections and Delayed CD4+ T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation. Transplantation and Cellular Therapy, 2021, 27, 940-948. | 0.6 | 20 |
| 54 | Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids. Haematologica, 2011, 96, 1351-1356. | 1.7 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Pretransplantation 5-Azacitidine in High-Risk Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2014, 20, 776-780. | 2.0 | 19 |
| 56 | Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease. Haematologica, 2015, 100, 970-977. | 1.7 | 19 |
| 57 | Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal study. Bone Marrow Transplantation, 2019, 54, 1354-1360. | 1.3 | 19 |
| 58 | TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 753-758. | 0.2 | 18 |
| 59 | Allogeneic Hematopoietic Cell Transplantation for Richter Syndrome: A Single-Center Experience. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e35-e39. | 0.2 | 18 |
| 60 | Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2019, 25, 683-688. | 2.0 | 18 |
| 61 | Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Advances, 2020, 4, 3180-3190. | 2.5 | 18 |
| 62 | Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention. Bone Marrow Transplantation, 2017, 52, 1003-1009. | 1.3 | 17 |
| 63 | Outcomes of rituximabâ€BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. Cancer, 2020, 126, 2279-2287. | 2.0 | 17 |
| 64 | Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplantation and Cellular Therapy, 2022, 28, 111.e1-111.e8. | 0.6 | 16 |
| 65 | Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications. International Journal of Hematology, 2011, 93, 206-212. | 0.7 | 15 |
| 66 | Therapeutic Advances in the Treatment of Primary Plasma Cell Leukemia: A Focus on Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1144-1151. | 2.0 | 15 |
| 67 | Ofatumumab in Combination with Glucocorticoids for Primary Therapy of Chronic Graft-versus-Host Disease: Phase I Trial Results. Biology of Blood and Marrow Transplantation, 2015, 21, 1074-1082. | 2.0 | 14 |
| 68 | Vaccine therapy for cytomegalovirus in the setting of allogeneic hematopoietic cell transplantation. Expert Review of Vaccines, 2015, 14, 341-350. | 2.0 | 14 |
| 69 | Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience. Leukemia Research, 2018, 67, 1-5. | 0.4 | 14 |
| 70 | Sleep disruption among cancer patients following autologous hematopoietic cell transplantation. Bone Marrow Transplantation, 2018, 53, 307-314. | 1.3 | 14 |
| 71 | Comparison of outcomes of HCT in blast phase of BCR-ABL1â^' MPN with de novo AML and with AML following MDS. Blood Advances, 2020, 4, 4748-4757. | 2.5 | 14 |
| 72 | Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. Blood Advances, 2020, 4, 2084-2094. | 2.5 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1. Blood Advances, 2019, 3, 2525-2536. | 2.5 | 13 |
| 74 | Acute patientâ€reported outcomes in Bâ€cell malignancies treated with axicabtagene ciloleucel. Cancer Medicine, 2021, 10, 1936-1943. | 1.3 | 13 |
| 75 | An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. Bone Marrow Transplantation, 2021, 56, 3068-3077. | 1.3 | 13 |
| 76 | Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma. Blood Advances, 2022, 6, 3767-3778. | 2.5 | 13 |
| 77 | Three-dimensional conformal radiotherapy for astrocytic tumors involving the eloquent area in children and young adults. Journal of Neuro-Oncology, 2002, 60, 177-183. | 1.4 | 12 |
| 78 | Phase II Study of CD4+-Guided Pentostatin Lymphodepletion and Pharmacokinetically Targeted Busulfan as Conditioning for Hematopoietic Cell Allografting. Biology of Blood and Marrow Transplantation, 2013, 19, 1087-1093. | 2.0 | 12 |
| 79 | A Critical Appraisal of Extracorporeal Photopheresis as a Treatment Modality for Acute and Chronic Graft-Versus-Host Disease. Biomedicines, 2017, 5, 60. | 1.4 | 12 |
| 80 | Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. Biology of Blood and Marrow Transplantation, 2019, 25, 1099-1106. | 2.0 | 12 |
| 81 | GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. Blood Advances, 2019, 3, 1441-1449. | 2.5 | 12 |
| 82 | Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma. Cancer Research, 2020, 80, 5344-5354. | 0.4 | 12 |
| 83 | ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 256.e1-256.e7. | 0.6 | 12 |
| 84 | Impact of infused CD34+ stem cell dosing for allogeneic peripheral blood stem cell transplantation with post-transplant cyclophosphamide. Bone Marrow Transplantation, 2021, 56, 1683-1690. | 1.3 | 12 |
| 85 | Incidence and impact of community respiratory viral infections in postâ€transplant cyclophosphamideâ€based graftâ€versusâ€host disease prophylaxis and haploidentical stem cell transplantation. British Journal of Haematology, 2021, 194, 145-157. | 1.2 | 12 |
| 86 | Monoclonal Antibodies in Conditioning Regimens forÂHematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1288-1300. | 2.0 | 11 |
| 87 | Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment. Current Hematologic Malignancy Reports, 2016, 11, 118-126. | 1.2 | 11 |
| 88 | Boosting humoral and cellular immunity to pneumococcus by vaccination before and just after autologous transplant for myeloma. Bone Marrow Transplantation, 2016, 51, 291-294. | 1.3 | 11 |
| 89 | Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. Biology of Blood and Marrow Transplantation, 2018, 24, 2443-2449. | 2.0 | 11 |
| 90 | Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results. Clinical Cancer Research, 2021, 27, 2712-2722. | 3.2 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission. Bone Marrow Transplantation, 2014, 49, 11-16. | 1.3 | 10 |
| 92 | Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 480-487. | 2.0 | 10 |
| 93 | Objective and subjective physical function in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplantation, 2021, 56, 2897-2903. | 1.3 | 10 |
| 94 | Hypoalbuminaemia segregates different prognostic subgroups within the refined standard risk acute graftâ€versusâ€host disease score. British Journal of Haematology, 2018, 180, 854-862. | 1.2 | 9 |
| 95 | Sequence of Therapy in Multiple Myeloma: Does It Matter? Retrospective Evaluation of Patients with Multiple Myeloma Who Have Received Bortezomib Followed by Lenalidomide or Vice Versa,. Blood, 2011, 118, 3979-3979. | 0.6 | 9 |
| 96 | Myeloablative Intravenous Pharmacokinetically Targeted Busulfan Plus Fludarabine As Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With Non-Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 335-340. | 0.2 | 8 |
| 97 | Therapeutic strategies for cytomegalovirus in allogeneic hematopoietic cell transplantation. Immunotherapy, 2015, 7, 1059-1071. | 1.0 | 8 |
| 98 | Assessment of Clonotypic Rearrangements and Minimal Residual Disease in Lymphoid Malignancies. Archives of Pathology and Laboratory Medicine, 2022, 146, 485-493. | 1.2 | 8 |
| 99 | Primary plasmacytoma involving mediastinal lymph nodes: A diagnostic mimicry of primary mediastinal lymphoma. Hematology/ Oncology and Stem Cell Therapy, 2016, 9, 26-29. | 0.6 | 7 |
| 100 | Severe Action Tremor Related to Interferon-Alpha 2b Therapy for Malignant Melanoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 526. | 0.6 | 6 |
| 101 | Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia. Leukemia and Lymphoma, 2020, 61, 1678-1687. | 0.6 | 6 |
| 102 | Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 2108-2117. | 1.3 | 6 |
| 103 | Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL. Blood Advances, 2022, 6, 3970-3973. | 2.5 | 6 |
| 104 | Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience. Bone Marrow Transplantation, 2015, 50, 1487-1489. | 1.3 | 5 |
| 105 | Integrating Genomics in Myelodysplastic Syndrome to Predict Outcomes After Allogeneic Hematopoietic Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 7-13. | 0.2 | 5 |
| 106 | Insights on Genomic and Molecular Alterations in Multiple Myeloma and Their Incorporation towards Risk-Adapted Treatment Strategy: Concise Clinical Review. International Journal of Genomics, 2017, 2017, 1-6. | 0.8 | 5 |
| 107 | Haploidentical transplantation as a promising therapy for relapsed hemophagocytic lymphohistiocytosis in an older adult patient. Hematology/ Oncology and Stem Cell Therapy, 2018, 11, 96-98. | 0.6 | 5 |
| 108 | Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study. Biology of Blood and Marrow Transplantation, 2018, 24, 400-405. | 2.0 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma. Transplantation and Cellular Therapy, 2021, 27, 242.e1-242.e6. | 0.6 | 5 |
| 110 | Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Advances, 2022, 6, 828-847. | 2.5 | 5 |
| 111 | A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease. Blood Advances, 2022, 6, 259-269. | 2.5 | 5 |
| 112 | Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. Blood Advances, 2022, 6, 3991-3995. | 2.5 | 5 |
| 113 | Immunotherapy strategies for multiple myeloma: the present and the future. Immunotherapy, 2013, 5, 1005-1020. | 1.0 | 4 |
| 114 | Donor-derived constitutional chromosomal abnormalities after allogeneic hematopoietic cell transplantation: a single-center experience and a review of the literature. Bone Marrow Transplantation, 2015, 50, 1388-1392. | 1.3 | 4 |
| 115 | Autologous Stem Cell Transplantation in Central Nervous System Lymphoma: A Multicenter Retrospective Series and a Review of the Literature. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e273-e280. | 0.2 | 4 |
| 116 | Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma. Transplantation and Cellular Therapy, 2021, 27, 768.e1-768.e6. | 0.6 | 4 |
| 117 | Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. Bone Marrow Transplantation, 2022, 57, 31-37. | 1.3 | 4 |
| 118 | Allogeneic hematopoietic cell transplantation for myelofibrosis: A 10â€year experience at single institution. American Journal of Hematology, 2010, 85, 904-907. | 2.0 | 3 |
| 119 | Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. Transplantation and Cellular Therapy, 2022, 28, 187.e1-187.e10. | 0.6 | 3 |
| 120 | A Multidisciplinary Approach for Bone Metastases. Journal of Pain and Symptom Management, 2010, 39, 346-347. | 0.6 | 2 |
| 121 | Hepatobiliary manifestations of acute myeloid leukemia. Leukemia Research, 2011, 35, e81-e83. | 0.4 | 2 |
| 122 | A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients. Bone Marrow Transplantation, 2022, 57, 295-298. | 1.3 | 2 |
| 123 | Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 185.e1-185.e7. | 0.6 | 2 |
| 124 | Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined <scp>CIBMTR</scp>/<scp>CMWP</scp> ofÂ<scp>EBMT</scp> analysis. British Journal of Haematology, 2022, 198, 785-789. | 1.2 | 2 |
| 125 | Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. Bone Marrow Transplantation, 2018, 53, 932-937. | 1.3 | 1 |
| 126 | ELN 2017 Risk Classification Predicts Survival of AML Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, S112. | 2.0 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Sirolimus/Tacrolimus Facilitates Preferential Recovery of Regulatory T Cells (Treg) After Allogeneic Hematopoietic Cell Transplantation (HCT), and Is More Effective Than Methotrexate/Tacrolimus in Preventing Grade II-IV Acute Graft Vs. Host Disease (GVHD) and Moderate to Severe Chronic Gvhd. Blood, 2011, 118, 323-323. | 0.6 | 1 |
| 128 | A Phase 2 Study of Bortezomib Plus High-Dose Melphalan (Mel/Vel) Conditioning for Autologous Hematopoietic Cell Transplantation In Multiple Myeloma,. Blood, 2011, 118, 4158-4158. | 0.6 | 1 |
| 129 | Alternative Dosing of Cyclophosphamide, Bortezomib and Corticosteroids (CyBorD) for Relapsed/Refractory Multiple Myeloma. Blood, 2011, 118, 5142-5142. | 0.6 | 1 |
| 130 | Outcomes Analysis of Doublets of Novel Agents with Corticosteroids Versus Regimens with 3 or More Agents for Multiple Myeloma (MM): A Retrospective Analysis. Blood, 2011, 118, 1878-1878. | 0.6 | 1 |
| 131 | Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation?. British Journal of Haematology, 2022, 197, 326-338. | 1.2 | 1 |
| 132 | Multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic transplantation for high-risk multiple myeloma: Results of the BMT CTN 1302 Trial. Transplantation and Cellular Therapy, 2022, , . | 0.6 | 1 |
| 133 | Three-drug versus two-drug induction therapy regimens for patients with transplant-eligible multiple myeloma. The Cochrane Library, 0, , . | 1.5 | 0 |
| 134 | Allo-HCT regimens with low toxicity needed in older patients with acute myeloid leukaemia. Lancet Oncology, The, 2016, 17, e1. | 5.1 | 0 |
| 135 | Accelerated fractionated radiation by concomitant boost (AFX-CB) with concurrent cis-platinum (CDDP) for advanced nasopharyngeal carcinoma. Journal of Clinical Oncology, 2006, 24, 5540-5540. | 0.8 | 0 |
| 136 | Relapsed and Refractory Multiple Myeloma. Emerging Cancer Therapeutics, 2010, 1, 383-402. | 0.1 | 0 |
| 137 | Allogeneic Hematopoietic Cell Transplantation for Consolidation of VGPR or CR In Myeloma. Blood, 2011, 118, 4581-4581. | 0.6 | 0 |
| 138 | Phase II Study of a Novel Reduced Toxicity Preparative Regimen for Hematopoietic Cell Allografting Combining Pentostatin (Nipent) and Targeted Doses of Intravenous Busulfan (Busulfex) with or without Rituximab (PBÂ±R) Using a Novel Principle of CD4-Guided Immune Suppression. Blood, 2011, 118, 3022-3022. | 0.6 | 0 |
| 139 | Comparison of Sirolimus and Mycophenolate Mofetil As Salvage Treatment for Acute Graft-Versus-Host Disease. Blood, 2011, 118, 4548-4548. | 0.6 | 0 |
| 140 | Clinicohistologic Assessment of Bone Marrow Engraftment In Patients with Hematologic Malignancies Received Double Umbilical Cord Blood Transplantation â€“ A Single Institutional Observation. Blood, 2011, 118, 4578-4578. | 0.6 | 0 |
| 141 | Impact of Splenomegaly in the Presence of Negative PET FDG Avidity on Allogeneic Hematopoietic Cell Transplant Outcomes in Patients with Lymphoid Malignancies. Blood, 2015, 126, 5524-5524. | 0.6 | 0 |
| 142 | Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T-Cell Lymphomas As Front-Line Consolidation or in the Relapsed/Refractory Setting: A Meta-Analysis. Blood, 2015, 126, 4493-4493. | 0.6 | 0 |
| 143 | Hypo-Albuminemia at Day+90 after Allogeneic Hematopoietic Cell Transplantation for Lymphoid Malignancies Independently Predicts for Inferior Overall Survival and Higher Non-Relapse Mortality. Blood, 2015, 126, 4407-4407. | 0.6 | 0 |
| 144 | Reduced-Intensity or Myeloablative Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: A Side-By-Side Systematic Review/Meta-Analysis. Blood, 2016, 128, 3551-3551. | 0.6 | 0 |